841 related articles for article (PubMed ID: 16648370)
1. Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice.
Green BD; Lavery KS; Irwin N; O'harte FP; Harriott P; Greer B; Bailey CJ; Flatt PR
J Pharmacol Exp Ther; 2006 Aug; 318(2):914-21. PubMed ID: 16648370
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob/ob) mice.
Irwin N; McClean PL; Flatt PR
J Pept Sci; 2007 Jun; 13(6):400-5. PubMed ID: 17486662
[TBL] [Abstract][Full Text] [Related]
3. Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice.
Moritoh Y; Takeuchi K; Asakawa T; Kataoka O; Odaka H
Eur J Pharmacol; 2008 Jul; 588(2-3):325-32. PubMed ID: 18499100
[TBL] [Abstract][Full Text] [Related]
4. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
Green BD; Gault VA; O'Harte FP; Flatt PR
Diabetes Obes Metab; 2005 Sep; 7(5):595-604. PubMed ID: 16050953
[TBL] [Abstract][Full Text] [Related]
5. Glucagon-like peptide-2 receptor modulates islet adaptation to metabolic stress in the ob/ob mouse.
Bahrami J; Longuet C; Baggio LL; Li K; Drucker DJ
Gastroenterology; 2010 Sep; 139(3):857-68. PubMed ID: 20546737
[TBL] [Abstract][Full Text] [Related]
6. Preparation, characterization, and application of biotinylated and biotin-PEGylated glucagon-like peptide-1 analogues for enhanced oral delivery.
Chae SY; Jin CH; Shin HJ; Youn YS; Lee S; Lee KC
Bioconjug Chem; 2008 Jan; 19(1):334-41. PubMed ID: 18078308
[TBL] [Abstract][Full Text] [Related]
7. Glucagon-like peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis.
Lee YS; Shin S; Shigihara T; Hahm E; Liu MJ; Han J; Yoon JW; Jun HS
Diabetes; 2007 Jun; 56(6):1671-9. PubMed ID: 17369525
[TBL] [Abstract][Full Text] [Related]
8. DPP-4 inhibition improves glucose tolerance and increases insulin and GLP-1 responses to gastric glucose in association with normalized islet topography in mice with beta-cell-specific overexpression of human islet amyloid polypeptide.
Ahrén B; Winzell MS; Wierup N; Sundler F; Burkey B; Hughes TE
Regul Pept; 2007 Oct; 143(1-3):97-103. PubMed ID: 17482289
[TBL] [Abstract][Full Text] [Related]
9. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes.
Mu J; Woods J; Zhou YP; Roy RS; Li Z; Zycband E; Feng Y; Zhu L; Li C; Howard AD; Moller DE; Thornberry NA; Zhang BB
Diabetes; 2006 Jun; 55(6):1695-704. PubMed ID: 16731832
[TBL] [Abstract][Full Text] [Related]
10. Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1(9-36)amide, on insulin secretion and glucose homeostasis in ob/ob mice.
Parker JC; Lavery KS; Irwin N; Green BD; Greer B; Harriott P; O'Harte FP; Gault VA; Flatt PR
J Endocrinol; 2006 Oct; 191(1):93-100. PubMed ID: 17065392
[TBL] [Abstract][Full Text] [Related]
11. Antidiabetic effects of dipeptidyl peptidase-IV inhibitors and sulfonylureas in streptozotocin-nicotinamide-induced mildly diabetic mice.
Matsuyama-Yokono A; Tahara A; Nakano R; Someya Y; Shiraki K; Hayakawa M; Shibasaki M
Metabolism; 2009 Mar; 58(3):379-86. PubMed ID: 19217455
[TBL] [Abstract][Full Text] [Related]
12. Biological activity of AC3174, a peptide analog of exendin-4.
Hargrove DM; Kendall ES; Reynolds JM; Lwin AN; Herich JP; Smith PA; Gedulin BR; Flanagan SD; Jodka CM; Hoyt JA; McCowen KM; Parkes DG; Anderson CM
Regul Pept; 2007 Jun; 141(1-3):113-9. PubMed ID: 17292977
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment: Insulinotropic activity, glucose-stabilizing capability, and proteolytic stability.
Youn YS; Chae SY; Lee S; Jeon JE; Shin HG; Lee KC
Biochem Pharmacol; 2007 Jan; 73(1):84-93. PubMed ID: 17054919
[TBL] [Abstract][Full Text] [Related]
14. How the hindgut can cure type 2 diabetes. Ileal transposition improves glucose metabolism and beta-cell function in Goto-kakizaki rats through an enhanced Proglucagon gene expression and L-cell number.
Patriti A; Aisa MC; Annetti C; Sidoni A; Galli F; Ferri I; Gullà N; Donini A
Surgery; 2007 Jul; 142(1):74-85. PubMed ID: 17630003
[TBL] [Abstract][Full Text] [Related]
15. Therapies for the treatment of type 2 diabetes mellitus based on incretin action.
Gallwitz B
Minerva Endocrinol; 2006 Jun; 31(2):133-47. PubMed ID: 16682937
[TBL] [Abstract][Full Text] [Related]
16. Protective effect of brain-derived neurotrophic factor on pancreatic islets in obese diabetic mice.
Yamanaka M; Itakura Y; Inoue T; Tsuchida A; Nakagawa T; Noguchi H; Taiji M
Metabolism; 2006 Oct; 55(10):1286-92. PubMed ID: 16979397
[TBL] [Abstract][Full Text] [Related]
17. Duodenal-jejunal bypass protects GK rats from {beta}-cell loss and aggravation of hyperglycemia and increases enteroendocrine cells coexpressing GIP and GLP-1.
Speck M; Cho YM; Asadi A; Rubino F; Kieffer TJ
Am J Physiol Endocrinol Metab; 2011 May; 300(5):E923-32. PubMed ID: 21304061
[TBL] [Abstract][Full Text] [Related]
18. Improvement of metabolic state in an animal model of nutrition-dependent type 2 diabetes following treatment with S 23521, a new glucagon-like peptide 1 (GLP-1) analogue.
Uçkaya G; Delagrange P; Chavanieu A; Grassy G; Berthault MF; Ktorza A; Cerasi E; Leibowitz G; Kaiser N
J Endocrinol; 2005 Mar; 184(3):505-13. PubMed ID: 15749809
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the antidiabetic activity of DPP IV resistant N-terminally modified versus mid-chain acylated analogues of glucose-dependent insulinotropic polypeptide.
Irwin N; Clarke GC; Green BD; Greer B; Harriott P; Gault VA; O'Harte FP; Flatt PR
Biochem Pharmacol; 2006 Sep; 72(6):719-28. PubMed ID: 16859646
[TBL] [Abstract][Full Text] [Related]
20. Incretins and other peptides in the treatment of diabetes.
Todd JF; Bloom SR
Diabet Med; 2007 Mar; 24(3):223-32. PubMed ID: 17263764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]